Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia

Study Reported Overall Response Rate of 38%, and REVLIMID® (Lenalidomide) Was Well Tolerated
BOUDRY, Switzerland–(BUSINESS WIRE)–Dec. 11, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID® (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. The findings were presented during the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA. Read more of this entry

About these ads

Tags: , ,

Categories: Life Sciences Industry Network

Author:New Jersey Technology Council

The New Jersey Technology Council provides business support, networking opportunities, information, advocacy and recognition of technology companies and their leaders. Founded in 1996, NJTC's almost 1,000 member companies work together to support their own enterprises while advancing New Jersey's status as a leading technology center in the United States.

NJTC TechWire

Daily updates about the region's most tech savvy companies

Trackbacks/Pingbacks

  1. Industry News » Blog Archive » Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia - December 12, 2011

    […] from: Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia Tags: archives, careers, digital-video, energy, health, oracle, prevention, revlimid®, technology, […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 86 other followers

%d bloggers like this: